<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00215202</url>
  </required_header>
  <id_info>
    <org_study_id>D0327</org_study_id>
    <nct_id>NCT00215202</nct_id>
  </id_info>
  <brief_title>Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)</brief_title>
  <official_title>A Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kentuckiana Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of Iressa will result in a greater than 20% response rate in patients with&#xD;
      nonresectable adrenocortical cancer who have previously been treated with one other form of&#xD;
      systemic therapy (either Mitotane or chemotherapy).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adrenocortical carcinoma is a rare cancer with an incidence of 1.5 to 2 per million people in&#xD;
      the United States. Surgery is the only potentially curative option. Current systemic therapy,&#xD;
      either Mitotane or chemotherapy, typically gives response rates of 20% or less. This study is&#xD;
      designed to see if the newer targeted therapy, Iressa, may be of benefit for patients with&#xD;
      this fatal disease.&#xD;
&#xD;
      Patients with nonresectable adrenocortical cancer who have progressed on at least one other&#xD;
      form of systemic therapy (Mitotane or chemotherapy) will be given Iressa 250 mg by mouth&#xD;
      daily until disease progression. This is a standard two-stage Phase II clinical trial.&#xD;
      Eighteen patients with measurable disease will be enrolled in the first stage. If there is at&#xD;
      least one responder, then an additional nine patients with measurable disease will be&#xD;
      enrolled for a total of 27 patients with measurable disease. Up to six patients without&#xD;
      measurable disease may be enrolled at any point in this study. Iressa will be provided free&#xD;
      for all study participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to measure the objective response rate by RECIST (radiographic) criteria of nonresectable adrenocortical cancer to ZD1839</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event profile</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <enrollment type="Actual">16</enrollment>
  <condition>Nonresectable Adrenocortical Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iressa (ZD1839)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must be able to provide informed consent&#xD;
&#xD;
          -  Subject must be 18 years of age or older&#xD;
&#xD;
          -  Subject must have histologically confirmed ACC by Department of Pathology at Dartmouth&#xD;
             Hitchcock Medical Center&#xD;
&#xD;
          -  Subject must have inoperable disease&#xD;
&#xD;
          -  Subject must have received some form of systemic therapy prior to enrolling in the&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known severe hypersensitivity to Iressa&#xD;
&#xD;
          -  other co-existing malignancies diagnosed within the last five years except basal cell&#xD;
             cancer or cervical cancer in situ&#xD;
&#xD;
          -  any unresolved CTC grade 2 toxicity from previous anticancer therapy (except alopecia)&#xD;
&#xD;
          -  absolute neutrophil count less than 1.5 x 1,000,000,000 per liter&#xD;
&#xD;
          -  platelets less than 20 x 1,000,000,000 per liter&#xD;
&#xD;
          -  severe uncontrolled systemic disease&#xD;
&#xD;
          -  pregnancy\breastfeeding&#xD;
&#xD;
          -  women who are fertile and not willing to practice abstinence or contraception&#xD;
&#xD;
          -  use of phenytoin, carbamazepine, rifampicin, barbiturates, or St. John's Wort&#xD;
&#xD;
          -  treatment with a non-approved or investigational drug within 28 days before Day 1 of&#xD;
             study treatment&#xD;
&#xD;
          -  prior use of ZD1839 (Iressa) or any other anti-EGFR therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivek Samnotra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kentuckiana Cancer Institute PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>September 15, 2005</study_first_submitted>
  <study_first_submitted_qc>September 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <keyword>Adrenocortical Cancer</keyword>
  <keyword>Iressa</keyword>
  <keyword>Adrenal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adrenocortical Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

